250
Participants
Start Date
August 9, 2019
Primary Completion Date
March 31, 2027
Study Completion Date
March 31, 2027
CCS1477
Oral capsule
Pomalidomide
oral capsule
Dexamethasone
oral tablet
Azacitidine
Powder suspension for Injection
Venetoclax
Oral tablet
RECRUITING
Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
RECRUITING
The Center for Cancer and Blood Disorders (CCBD), Bethesda
COMPLETED
CIOCC Hospital Universitario HM Sanchinarro, Madrid
RECRUITING
Emory Winship Cancer Institute, Atlanta
RECRUITING
Community Health Network, Indianapolis
RECRUITING
Nebraska Cancer Specialists, Omaha
RECRUITING
University of Nebraska Medical Center, Omaha
COMPLETED
University Hospital Vall D'Hebron, Barcelona
RECRUITING
The Royal Marsden, Sutton
RECRUITING
The Clatterbridge Cancer Centre NHS Foundation Trust,, Bebington
RECRUITING
University Hospitals Bristol, Bristol
RECRUITING
University Hospital of Wales, Cardiff
RECRUITING
Leicester Royal Infirmary, Leicester
RECRUITING
Imperial College, London
RECRUITING
The Christie Hospital, Manchester
RECRUITING
Newcastle upon Tyne Hospitals, Newcastle upon Tyne
RECRUITING
Cancer and Haematology Centre, Oxford
RECRUITING
Royal Derby Hospital, Derby
RECRUITING
Western General Hospital, Edinburgh
RECRUITING
Gartnavel General Hospital, Glasgow
RECRUITING
Sarah Cannon Research Institute UK, London
RECRUITING
NIHR University College London Clinical Research Facility, London
RECRUITING
University Hospital of Southampton, Southampton
Lead Sponsor
CellCentric Ltd.
INDUSTRY